This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carter, L. P. Articles by Temeltas, O. Search for Related Content PubMed PubMed Citation Articles by Carter, L. P. Articles by Temeltas, O.

Stroke, Vol 23, 883-888, Copyright © 1992 by American Heart Association

ARTICLES

Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model

LP Carter, AN Guthkelch, J Orozco and O Temeltas
Department of Surgery (Section of Neurosurgery), University of Arizona, Tucson.

BACKGROUND AND PURPOSE: The aims of this study were to verify that tissue-type plasminogen activator given either 1 or 2 hours after experimental embolic stroke in rabbits diminishes the volume of resulting ischemic brain and to ascertain the effect of the simultaneous administration of heparin. METHODS: We embolized the middle cerebral artery of rabbits by injecting performed autologous arterial ("white") thrombus into one internal carotid artery. Treatment with 2 mg/kg tissue-type plasminogen activator, alone or in combination with heparin, was commenced either 1 or 2 hours after embolization. The animals were killed 5 hours after treatment commenced, and their brains were examined for evidence of ischemia and hemorrhage. RESULTS: Administration of tissue-type plasminogen activator significantly diminished the size of the resulting brain ischemia. Administration of heparin, with or instead of tissue-type plasminogen activator, did not result in a significant decrease in the volume of cerebral ischemia, but it also did not lead to hemorrhagic transformation of the stroke. CONCLUSIONS: In the rabbit model, administration of tissue-type plasminogen activator within 2 hours diminished the volume of brain rendered acutely ischemic by embolic stroke. Since the simultaneous administration of heparin during this same period did not result in any instances of hemorrhagic transformation, tissue-type plasminogen activator may have some place for use in such circumstances to mitigate a tendency to further embolic or thrombotic events.

This article has been cited by other articles:

				K. Kirchhof, T. Welzel, S. Zoubaa, C. Lichy, M. Sikinger, H. L. de Ruiz, and K. Sartor New Method of Embolus Preparation for Standardized Embolic Stroke in Rabbits Stroke, September 1, 2002; 33(9): 2329 - 2333. [Abstract] [Full Text] [PDF]

				S. JONAS, V. AIYAGARI, D. VIEIRA, and M. FIGUEROA The Failure of Neuronal Protective Agents Versus the Success of Thrombolysis in the Treatment of Ischemic Stroke: The Predictive Value of Animal Models Ann. N.Y. Acad. Sci., June 1, 2001; 939(1): 257 - 267. [Abstract] [Full Text] [PDF]

				S. Vanderschueren, I. Van Vlaenderen, and D. Collen Intravenous Thrombolysis With Recombinant Staphylokinase Versus Tissue-Type Plasminogen Activator in a Rabbit Embolic Stroke Model Stroke, September 1, 1997; 28(9): 1783 - 1788. [Abstract] [Full Text]